Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Peretz, C.A.C et al.
Blood Advances (2021)

Acute myeloid leukemia (AML) with activated Fms-like tyrosine kinase receptor III (FLT3) causes significant mortality secondary to relapsed/refractory (R/R) disease. Drug resistance limits the duration of response of FLT3 inhibitors (FLT3i). Genetic evolution leading to R/R disease is incompletely understood, and leukemia’s heterogeneity is incompletely described, even with next-generation sequencing (NGS). A deeper understanding of cellular heterogeneity is essential because intratumoral heterogeneity is ubiquitous, has prognostic relevance, affects response to therapy, and drives therapeutic resistance. We characterized, via single-cell sequencing (SCS), the genetic evolution of R/R AML on the FLT3i quizartinib.


Peretz, C.A.C, McGary, L.H.F, Kumar, T., Jackson, H., Jacob, J., Durruthy-Durruthy, R., Levis, M.J., Perl, A., Huang, B.J., Smith, C.C.


Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue
Sharma R
Blood (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao Y
Nature (2021)
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
Sahoo S.S.
Nature Medicine (2021)
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O.
Cancer Cell (2021)